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Abstract
Background: Childhood interstitial lung disease (chILD) is a heterogeneous group of rare disorders characterized
by abnormal imaging findings, impaired gas exchange; and is associated with substantial morbidity and mortality.
Neuroendocrine cell hyperplasia (NEHI) is a unique sub-group, which is more prevalent in infants and children
younger than 2 years of age, and typically manifests with chronic tachypnea, retractions, hypoxemia and failure
to thrive. NEHI insidiously appears in the first year of life, subtly masquerading as one of the more common lung
diseases of childhood. Therefore, the diagnosis of NEHI is challenging and requires a systematic approach.
Case presentation: We report a case of an infant, with a history of recurrent respiratory infections and wheezing,
who presented with persistent hypoxemia (PaO2 88 mmHg) and chronic respiratory symptoms, that prompted an
extensive diagnostic work up for chILD; eventually a diagnosis of NEHI was made.
Conclusion: NEHI is a rare chILD disorder presenting in the first 2 years of life with common but challenging key
clinical features. Increased awareness among pediatricians and prompt recognition of the clinical presentation may
enable timely diagnosis and improve disease management and prognosis.
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Background
Childhood interstitial lung disease (chILD) is a heteroge-
neous group of rare disorders characterized by abnormal
imaging findings, impaired gas exchange; and is associated
with substantial morbidity and mortality. [1]. A recent
revised classification identified neuroendocrine cell hyper-
plasia (NEHI) as a prevalent sub-type in infants and
children younger than 2 years of age [2, 3]. The chILD
clinical phenotype refers to children who meet at least three
of the following four criteria: (1) respiratory symptoms
(cough, tachypnea, or exercise intolerance), (2) signs
(resting tachypnea, adventitious sounds, retractions, digital
clubbing, failure to thrive or respiratory failure), (3) hypo-
xemia, and (4) specific diffuse abnormalities on chest
imaging [1]. In infancy, the clinical features of chILD may
be non-specific, occasionally subtle and masquerade as
more common lung diseases in childhood (eg, cystic
fibrosis, immunodeficiency, or congenital heart disease).
Therefore, establishing a specific diagnosis of chILD is
challenging and requires a systematic approach.
We report a case of an infant, with a history of recurrent
respiratory infections and wheezing, who presented with
persistent hypoxemia (PaO2 88 mmHg) and chronic
respiratory symptoms, that prompted an extensive diag-
nostic work up for chILD; eventually a diagnosis of NEHI
was made.
Case presentation
The patient, a 5-month-old boy, was delivered full-term
and vaginally without complications. The neonatal course
was uneventful. At discharge, he was exclusively breastfed
and his weight and length were in the 50th percentile.
A family history revealed consanguineous parents com-
ing from Northern Africa; the mother had a history of two
miscarriages before the birth of his older siblings. His
elder brother had asthma and presented with abnorma-
lities of the rib cage, while his sister underwent surgical
treatment for transposition of the great vessels.
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At age 3 months, after a chickenpox infection, he
experienced his first respiratory exacerbation followed
by recurrent wheezing associated with airway infections,
that required frequent admissions to the emergency room
and treatment with inhaled beta2-adrenergic drugs, anti-
biotics and oral steroids. The child had received all of the
mandatory and recommended vaccines for his age; he had
no allergies and no history of apparent prior failure to
thrive. At the age of 5 months, he was admitted to our
Pediatric Unit for acute respiratory distress in a frame-
work of suspected viral bronchiolitis. He presented with
tachypnea (103/min), retractions, and hypoxemia (oxygen
saturation on room air at 88 % at rest), requiring oxygen
supplementation. Expiratory wheezing and crackling
were the main respiratory auscultation findings. A clinical
examination also revealed a significant reduction in growth
velocity (both weight and length from the 50th to 10th
percentile). Blood gas analysis revealed a respiratory
acidosis (pH: 7,30; PaCO2: 48 mmHg; HCO3: 19 mmol/l).
A chest radiograph revealed over-inflation of the lungs
with some interstitial markings in the pulmonary hilum
and right upper lobe. Nasal secretions were analyzed for
respiratory syncytial virus, rhinovirus, influenza virus,
parainfluenza virus and adenovirus; all resulted negative.
After a first therapeutic trial with nebulized β2-adrenergic
agonists without improvement of symptoms, he was treated
with respiratory support in combination with appropriate
fluid and nutrition management.
Considering the persistent hypoxemia, despite supple-
mental oxygen support together with the associated
pronounced respiratory distress and the clinical and radio-
logical findings, the bronchiolitis diagnosis was determined
to be misleading and an extensive diagnostic workup was
performed. Complete blood count and measurement of
serum immunoglobulin levels were normal; sweat test,
serological tests for bacterial infections (Chlamydia and
Mycoplasma pneumoniae, Bordetella pertussis), echocar-
diography and intraluminal impedance pH monitoring
were negative. Assessment of the ciliary ultrastructure, beat
frequency and pattern from a brush biopsy of the nasal
epithelium excluded the diagnosis of primary ciliary dys-
kinesia. Subsequently, genetic testing for all exons encoding
the ABCA3 surfactant gene (ATP-binding cassette 3) and
the SFTPC gene (surfactant protein C) was carried out
for suspected genetic surfactant disorders, with negative
results. A diagnostic bronchoscopy excluded airway mala-
cia and a bronchoalveolar lavage (BAL) revealed the high
prevalence of neutrophils and the presence of slightly
enlarged lymphocyte aggregates and macrophages with
intracellular lipids. Microbiological examination of the BAL
fluid showed an important colonization by Streptococcus
pneumnoniae, Moraxella catarrhalis, Rhinovirus and
Adenovirus. Meanwhile, high-resolution chest computed
tomography (HRCT) showed air trapping in the left upper
lobe and both lower lobes, and ground-glass opacities of
the middle-upper lobes and of the lingula (Fig. 1). This
typical radiological pattern raised the possibility of neuro-
endocrine cell hyperplasia of infancy (NEHI). In order to
complete the diagnostic workup, an open lung biopsy
performed at 9 months of age showed the presence of areas
characterized by macrophage alveolitis associated with
neuroendocrine cell hyperplasia of the small airways.
Immunohistochemistry demonstrated a significant number
of bombesin-positive cells in the small airways walls (Fig. 2).
Finally, NEHI was diagnosed on the basis of radiological
and histopathological findings typical of NEHI, while
pulmonary interstitial glycogenosis was excluded with the
biopsy findings. The infant was initially treated with oral
prednisolone (1 mg/kg daily); afterwards, he required
long-term oxygen and nutritional supplementation.
At follow up visits he exhibited gradual clinical improve-
ment. At 12 months of age, oxygen support was admi-
nistered only at night. At the age of 18 months, his
respiratory rate improved and his growth values were back
within the normal range (50th percentile). At this time,
the daily dose of steroids was stopped. Currently, at age
2 years, he only requires symptomatic treatment of any
respiratory infection.
Conclusion
NEHI is a disorder of unknown etiology that typically
manifests with chronic tachypnea, retractions, hypoxemia
and failure to thrive, insidiously appearing in the first
year of life. Crackles are prominent on chest ausculta-
tion, while wheezing is uncommon [4, 5]. The inci-
dence and prevalence of NEHI, as well as its etiology,
are still unknown. Familial cases with affected siblings
have been reported, suggesting that there might be a
genetic predisposition [6, 7].
The chest radiograph may be normal or may reveal
hyperinflation with variable increased peri-hilar opacity
[8], whereas HRCT appears to be the most reliable non-
invasive imaging test that can point to the diagnosis of
NEHI and can differentiate NEHI from other types of
interstitial lung disease [9]. Multi-lobar ground-glass
opacity predominantly involving the right middle lobe
and lingula as well as a mosaic pattern of air-trapping
are typical findings on HRCT with a reported sensitivity
of 83 % and specificity of 100 %, thus limiting in some
cases the indication for a confirmatory lung biopsy [9].
Whenever available, lung function testing shows a pattern
of hyperinflation and airflow obstruction [10, 11]. Bron-
choscopy with BAL plays a role in excluding infection,
aspiration or haemorrhage, and in identifying pulmonary
alveolar proteinosis [12]; but lung biopsy remains the
gold standard for chILD when less invasive tests fail to
secure a diagnosis [1]. Lung biopsies in NEHI often show
an essentially normal histology on standard staining, with
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an increase in Bombesin-positive cells after specific stain-
ing [4, 13]. Nevertheless, it should be noted that hyper-
plasia of neuroendocrine cells is not specific for NEHI,
and has also been described in several other rare pediatric
lung diseases [13, 14].
In our report, the patient was initially hospitalized pre-
senting with non-specific features of acute hypoxemia,
crackles and tachypnea; his misleading clinical history of
recurrent episodes of wheezing associated with respira-
tory infections led to a first diagnosis of bronchiolitis
and resulted in a delayed NEHI diagnosis. Moreover, in
his first 5 months of life he did not present with failure
to thrive, which is one of the key features in chILD disor-
ders. The persistent hypoxemia and increased respiratory
effort raised concerns regarding the initial diagnosis.
Additionally, the clinical history of neonatal unexplained
tachypnea, the familiar history of thoracic abnormalities,
and evidence of a previously unrecognized failure to thrive
were all elements that led to the decision to perform an
extensive differential diagnostic work up. Overlapping com-
mon respiratory disorders that should be considered in the
clinical differential work up include infections, asthma, air-
way anomalies and injury, gastro-esophageal reflux, foreign
body aspiration, cystic fibrosis, primary ciliary diskinesia,
Fig. 1 Areas of interest: ground glass opacities in the medial portion of the upper lobes (a) and right middle lobe and lingula (b) with some
areas of consolidation in the lingula
Caimmi et al. Italian Journal of Pediatrics  (2016) 42:84 Page 3 of 5
immunodeficiency and congenital heart disease [1, 12].
In addition, other causes of chILD such as pulmonary
hypoplasia, pulmonary interstitial glycogenosis and genetic
disorders of surfactant production and metabolism needed
to be excluded [1, 15, 16].
There is no consensus on the therapy for NEHI, and
management generally consists of supportive care: supple-
mental oxygen for chronic hypoxemia, adequate nutrition,
proper immunization, avoidance of environmental pollu-
tants, and treatment of recurrent infections [4, 12]. In
some cases of chILD, steroids may also be used to
improve the clinical picture, but with close monitoring of
side effects [12].
The long-term outcome of NEHI is generally favourable
with most patients gradually improving over time, although
persistent airway obstruction mimicking severe asthma
and relapse with respiratory infection have also been
reported [17]. In our case, it was important to schedule a
close follow up of the patient who was at risk of develop-
ing severe asthma as well, since he has a family history of
asthma, exhibits macrophage alveolitis and has previously
undergone systemic steroidal therapy.
In conclusion, NEHI is a rare chILD disorder presenting
in the first 2 years of life with common but challenging
key clinical features, in particular hypoxemia, respiratory
distress and failure to thrive, and distinct imaging and
histological findings. Increased awareness among pediatri-
cians and prompt recognition of the clinical presentation
may enable timely diagnosis and improve disease manage-
ment and prognosis.
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